Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib

Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2011-02, Vol.28 (2), p.126-133
Main Authors: Heigener, David F., Reck, Martin
Format: Article
Language:English
Subjects:
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Cardiology
Clinical Trials as Topic
Disease-Free Survival
Drug Resistance, Neoplasm
Endocrinology
Erlotinib Hydrochloride
Genes, erbB-1
Health technology assessment
Humans
Internal Medicine
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Medicine
Medicine & Public Health
Molecular Targeted Therapy
Mutation
Oncology
Pharmacology/Toxicology
Protein Kinase Inhibitors - therapeutic use
Quinazolines - therapeutic use
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Review
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatment, is a problem of paramount importance. Several mechanisms of “acquired resistance” have been discovered and treatments for this specific entity are on the horizon.
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-010-0096-4